- Home
- EDF vs INMB Comparison
EDF vs INMB Comparison
Compare EDF & INMB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDF
- INMB
- Stock Information
- Founded
- EDF 2010
- INMB 2015
- Country
- EDF United States
- INMB United States
- Employees
- EDF N/A
- INMB N/A
- Industry
- EDF Investment Managers
- INMB Biotechnology: Pharmaceutical Preparations
- Sector
- EDF Finance
- INMB Health Care
- Exchange
- EDF Nasdaq
- INMB Nasdaq
- Market Cap
- EDF 148.8M
- INMB 176.5M
- IPO Year
- EDF N/A
- INMB 2019
- Fundamental
- Price
- EDF $5.06
- INMB $2.19
- Analyst Decision
- EDF
- INMB Strong Buy
- Analyst Count
- EDF 0
- INMB 3
- Target Price
- EDF N/A
- INMB $24.33
- AVG Volume (30 Days)
- EDF 160.6K
- INMB 5.5M
- Earning Date
- EDF 01-01-0001
- INMB 07-31-2025
- Dividend Yield
- EDF 13.14%
- INMB N/A
- EPS Growth
- EDF N/A
- INMB N/A
- EPS
- EDF N/A
- INMB N/A
- Revenue
- EDF N/A
- INMB $50,000.00
- Revenue This Year
- EDF N/A
- INMB $82.14
- Revenue Next Year
- EDF N/A
- INMB $28,750.98
- P/E Ratio
- EDF N/A
- INMB N/A
- Revenue Growth
- EDF N/A
- INMB N/A
- 52 Week Low
- EDF $3.51
- INMB $2.00
- 52 Week High
- EDF $5.50
- INMB $11.64
- Technical
- Relative Strength Index (RSI)
- EDF 60.99
- INMB 34.68
- Support Level
- EDF $4.96
- INMB $5.60
- Resistance Level
- EDF $5.07
- INMB $7.49
- Average True Range (ATR)
- EDF 0.06
- INMB 1.21
- MACD
- EDF -0.00
- INMB -0.18
- Stochastic Oscillator
- EDF 76.47
- INMB 4.83
About EDF Virtus Stone Harbor Emerging Markets Income Fund of Beneficial Interest
Virtus Stone Harbor Emerging Markets Income Fund is a closed-end management investment company. Its investment objective is to maximize total return, which consists of income from its investments and capital appreciation. The Fund normally will invest at least 80% of its net assets (plus any borrowings for investment purposes) in emerging markets securities.
About INMB INmune Bio Inc. Common stock
INmune Bio Inc is a clinical-stage biotechnology company. It is engaged in the development of new immunotherapies that reprogram a patient's innate immune system to allow immune system to fight cancer. The company's pipeline products includeINKmune, INBO3, XPro1595, LIVNate, and others.